Velg din region
Velg regionen som passer best for din plassering eller dine preferanser.
International
Sverige
Norge
Danmark
Suomi
United Kingdom
Deutschland
France
België
Nederland
Österreich
Schweiz
Italia
España
Velg ditt nettstedsspråk
Denne innstillingen kontrollerer språket for brukergrensesnittet, inkludert knapper, menyer og all tekst på nettstedet. Velg ditt foretrukne språk for best brukeropplevelse.
Engelsk
English
Svensk
Svenska
Norsk
Norsk
Dansk
Dansk
Finsk
Suomi
Tysk
Deutsch
Fransk
Français
Nederlandsk
Nederlands
Italiensk
Italiano
Spansk
Español
Velg språk for stillingsannonser
Velg språkene for stillingsannonser du vil se. Denne innstillingen bestemmer hvilke stillingsannonser som vises for deg.
The two founders still own approximately 75% of the company, the remainder is owned by key persons within the organization. The company is devoted to research and development of bone regenerative technologies and biomaterials. The company is performing early-stage, pre-clinical in vitro and animal studies and all of its inventions are within the field described above. The company’s main assets next to its researchers are its patents and patent applications. Since its inception, the company has successfully developed and licensed out/sold several patent portfolios to major players within the dental implant industry. The Company is focusing all its R & D on its three new technologies, a titanium based ceramic bone graft material (NuBone®), a synthetic peptide family (NuPep™) and a paste for peri-implantitis treatment (NuGel™).